Figure 3.

NKG2C-KE controls tumor as effectively as 161533 TriKE

(A) Schematic of mouse model. NSG mice were injected with 750,000 HL60-Luc cells, then 3 days later, BLI injected with 5 million thawed expanded NK cells. Mice received 5× weekly intraperitoneal (i.p.) injections of drug for 3 weeks; BLI at days 6, 13, 20, and 27; and bleeds at days 14 and 28. (B) Frozen expanded NK cells thawed and stained for CD16 and NKG2C. (C) Individual bioluminescence images separated into groups from days 6, 13, 20, 27, and 34. (D) Quantification of luminescence measured at days 0, 6, 13, 20, 27, and 34. (E) Blood from mice at days 14 and 28 stained for CD16 and NKG2C. Graphs indicate the means ± SDs analyzed using 2-way ANOVA and RM analysis used for (C) and (D). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.01, ∗∗∗∗p < 0.0001.